The AstraZeneca PLC ADR AZN inched 0.01% higher to $71.43 Monday, on what proved to be an all-around grim trading session ...

The pharmaceutical giant, whose China chief is now under investigation, was previously at the centre of insurance scam cases, ...

China's investigation of AstraZeneca's top executive in the country is raising questions about the company's tactics there.

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.

After AstraZeneca (AZN) presented data at the ObesityWeek conference, Deutsche Bank said the company’s oral small molecule GLP1 drug ...

As AstraZeneca’s chronic obstructive pulmonary disease drug Breztri continues climbing toward blockbuster status, the Big Pharma is broadening its efforts to support people with COPD. | As AstraZeneca ...

AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an ...

UBS analyst Matthew Weston maintained a Sell rating on AstraZeneca (AZN – Research Report) today and set a price target of £113.00. The ...

BEIJING—An investigation involving a top executive at drugmaker AstraZeneca is the latest to rattle foreign companies in ...

AstraZeneca and Eccogene revealed promising trial data on ECC5004, an oral GLP-1 receptor agonist for obesity, showing safety ...